for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Moderna Inc

MRNA.OQ

Latest Trade

161.38USD

Change

11.51(+7.68%)

Volume

1,599,980

Today's Range

150.50

 - 

162.43

52 Week Range

46.14

 - 

189.26

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
149.87
Open
150.60
Volume
1,599,980
3M AVG Volume
210.25
Today's High
162.43
Today's Low
150.50
52 Week High
189.26
52 Week Low
46.14
Shares Out (MIL)
401.53
Market Cap (MIL)
64,798.55
Forward P/E
6.01
Dividend (Yield %)
--

Next Event

Moderna Inc Science Day

Latest Developments

More

Moderna To Deliver 25 Mln Doses Of Its COVID-19 Vaccine To Australia

Moderna Reports Qtrly EPS Of $2.84

Moderna Expands Manufacturing Technology Center In Massachusetts

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Moderna Inc

Moderna, Inc. is engaged in transformative medicines based on messenger ribonucleic acid (mRNA). It has created a platform to improve the underlying pharmaceutical properties of our mRNA medicines. Its platform consists of three areas: mRNA technologies, delivery technologies, and manufacturing processes. It is pursuing mRNA science to minimize the undesirable activation of the immune system by mRNA and to maximize the potency of mRNA once in the target cells. It has advanced in parallel a diverse development pipeline of 21 programs, of which 10 have entered clinical studies and another three have open INDs. Its therapeutics and vaccine development programs span infectious diseases, oncology, cardiovascular diseases, and rare genetic diseases. It has created six modalities prophylactic vaccines, cancer vaccines, intratumoral immmuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics and systemic intracellular therapeutics.

Industry

Biotechnology & Drugs

Contact Info

200 Technology Sq

Cambridge, MA

02139-3578

United States

+1.617.7146500

https://www.modernatx.com/

Executive Leadership

Noubar B. Afeyan

Non-Executive Independent Chairman of the Board, Co-Founder

Stephen Hoge

President

Stephane Bancel

Chief Executive Officer, Director

David W. Meline

Chief Financial Officer

Tracey Franklin

Chief Human Resources Officer

Key Stats

2.56 mean rating - 16 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.1K

2019

0.1K

2020

0.8K

2021(E)

18.3K
EPS (USD)

2018

-4.950

2019

-1.550

2020

-1.960

2021(E)

24.929
Price To Earnings (TTM)
128.67
Price To Sales (TTM)
23.72
Price To Book (MRQ)
16.86
Price To Cash Flow (TTM)
101.73
Total Debt To Equity (MRQ)
4.77
LT Debt To Equity (MRQ)
3.60
Return on Investment (TTM)
19.34
Return on Equity (TTM)
8.10

Latest News

Latest News

Italian study shows COVID-19 infections, deaths plummeting after jabs

COVID-19 infections in adults of all ages fell by 80% five weeks after a first dose of Pfizer, Moderna or AstraZeneca vaccine, according to Italian research published on Saturday.

Samsung BioLogics says decision pending on making Moderna vaccine as report ignites share

Samsung BioLogics Co Ltd said on Friday no decision has been made yet on producing Moderna Inc's COVID-19 vaccine in South Korea after a newspaper reported the two companies had agreed on a contract manufacturing deal.

Samsung BioLogics says no decision yet on producing Moderna's COVID-19 shot

Samsung BioLogics Co Ltd said on Friday that no decision has been made yet on producing Moderna Inc's COVID-19 vaccine in South Korea after a local newspaper reported the two companies had agreed on a contract manufacturing deal.

Thailand reports record COVID-19 infections after prison clusters

Thailand announced a daily record in new coronavirus cases on Thursday after clusters in two jails saw nearly 3,000 inmates infected, among them a leader of anti-government protests held while awaiting trial for insulting the king.

Thailand grants emergency use approval for Moderna COVID-19 vaccine - official

Thailand's Food and Drug Administration (FDA) has given emergency use authorisation for the COVID-19 vaccine of Moderna Inc, an FDA official told Reuters on Thursday.

Australia seeks deal with Moderna for domestic production of mRNA vaccines

Australia is in talks with Moderna Inc to establish domestic manufacturing of messenger ribonucleic acid (mRNA) vaccines such as the company's COVID-19 vaccine, Prime Minister Scott Morrison said on Thursday.

Australia in 'active talks' with Moderna to locally produce mRNA vaccines

Australia is in "active talks" with COVID-19 vaccine maker Moderna Inc to establish a domestic manufacturing facility for mRNA vaccines, Health Minister Greg Hunt said on Thursday.

mRNA vaccines appear effective vs India variant; people with HIV at higher risk for severe COVID-19

The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.

Australia taps Moderna for 25 million COVID-19 shots in vaccination ramp up

Australia on Wednesday tapped Moderna Inc for 25 million COVID-19 vaccine doses, as it tries to speed up vaccination in people under 50 after deciding against AstraZeneca, whose jab has been linked to rare blood clots.

Moderna to deliver 25 million COVID-19 vaccine doses to Australia

Moderna Inc on Wednesday announced a supply pact with Australia for 25 million doses of its COVID-19 vaccine, of which 10 million doses against the original strain of the virus are to be delivered in 2021. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Arun Koyyur...

Poland to shorten gap between COVID vaccine doses

Poland will shorten the gap between doses for Pfizer, Moderna and AstraZeneca COVID-19 jabs, the minister responsible for Poland's vaccination programme said on Monday.

Takeda reports positive interim results of Moderna trials in Japan

Japanese drugmaker Takeda Pharmaceutical Co, which is importing Moderna Inc 's COVID-19 vaccine into Japan, said interim results of clinical trials ahead of domestic regulatory approvals have been positive.

Thailand set to boost COVID-19 vaccinations, expects to approve Moderna shots

Thailand expects to offer the Moderna vaccine to most of its population soon as it steps up the rollout of its COVID-19 vaccination campaign, a health official said on Saturday.

Unused COVID shots piling up in Japan amid slow rollout

Unused COVID-19 vaccines in Japan are set to reach tens of millions of doses, as the country is poised to approve two more shots in coming weeks and the pace of its inoculation campaign remains slow due to manpower and logistical bottlenecks.

Japan may approve AstraZeneca, Moderna vaccines as early as May 20 - Nikkei

Japan's government may approve the use of coronavirus vaccines developed by AstraZeneca PLC and Moderna Inc as early as May 20, the Nikkei reported on Friday.

Moderna sees no impact on COVID-19 vaccine from potential patent waiver

Moderna Inc on Thursday said it believes countries around the globe would continue buying its COVID-19 vaccine for years even if patents on the shots are waived, noting that rivals would face significant hurdles in scaling up manufacturing.

Moderna says waiving IP rights won't help increase vaccine supply

Moderna Inc said on Thursday that waiving intellectual property rights on COVID-19 vaccines will not help boost supply in 2021 or 2022, a day after U.S. President Joe Biden backed a proposed waiver that is aimed at giving poorer companies access.

Moderna raises 2021 sales forecast for COVID-19 vaccine to $19.2 bln

Moderna Inc raised its 2021 sales forecast for its COVID-19 vaccine by 4.3% to $19.2 billion on Thursday, reflecting demand from countries looking to return to normalcy through rapid inoculation.

Moderna booster increases antibodies against COVID-19 variants, early data shows

Moderna Inc said on Wednesday early human trial data shows that a third dose of either its current COVID-19 shot or an experimental new vaccine candidate increases immunity against variants of COVID-19 first found in Brazil and South Africa.

Moderna booster increases antibodies against COVID-19 variants, early data shows

Moderna Inc said on Wednesday early human trial data shows that a third dose of either its current COVID-19 shot or an experimental new vaccine candidate increases immunity against variants of COVID-19 first found in Brazil and South Africa.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up